Seeking Alpha
 

St. Jude Medical, Inc. (STJ)

- NYSE
  • Jul. 17, 2013, 7:59 AM
    More on St. Jude Medical (STJ +2.1%) Q2: net profit -53% to $115M, hurt by charges of $160M, primarily related to debt retirement. Adjusted net profit flat at $275M. Net sales also flat. Sales breakdown: Cardiac Rhythm Management -4% to $718M; Atrial Fibrillation +9% to $237M; Cardiovascular flat at $340M; neuromodulation +2% to $108M. Guidance: Q3 EPS of $0.88-0.90 vs consensus of $0.88; FY EPS of $3.70-3.73, increasing the lower range by $0.02 from prior forecast and vs analyst predictions of $3.69. (PR)
    | Comment!
  • Jul. 17, 2013, 7:31 AM
    St. Jude Medical (STJ): Q2 EPS of $0.96 beats by $0.02. Revenue of $1.40B beats by $0.04B. (PR)
    | Comment!
  • Jul. 17, 2013, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, FCFS, FRC, GWW, IGTE, MAT, MTB , NTRS, NVS, PNC, STJ, TXT, USB
    | Comment!
  • Jul. 16, 2013, 5:30 PM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, FCFS, FRC, GWW, IGTE, MAT, MTB , NTRS, NVS, PNC, STJ, TXT, USB
    | 2 Comments
  • Jun. 12, 2013, 1:07 PM
    Deutsche Bank (Buy) thinks the approval of St. Jude Medical's (STJ +2.6%) implantable cardioverter and cardiac resynchronization defibrillators is a "good sign," as it may signal that STJ is "making progress" with its efforts to allay concerns tied to an FDA inspection of the company's Sylmar, California manufacturing facility. Wedbush's Tao Levy concurs, noting that the FDA "viewed the safety enhancements of the Ellipse and Assura as important enough to approve despite the warning letter."
    | Comment!
  • Jun. 11, 2013, 4:47 PM
    St. Jude Medical (STJ) says it's received FDA approval for its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery.
    | Comment!
  • May. 31, 2013, 10:53 AM
    Wedbush initiates several medical equipment and supply names. Rundown: Boston Scientific (BSX +0.8%), which is "progressing with its turnaround story," is started at Neutral (price target $10) with new product intros serving as "catalysts for higher EPS"; Medtronic (MDT) is started at Neutral (price target $52) and is "an 800-lb. gorilla [facing] growing competition, limited near-term growth, and an overextended valuation"; St. Jude Medical (STJ -0.9%) is started at Outperform (price target $57) as the Durata overhang "is beginning to lose some steam enabling investors to refocus on STJ's healthy pipeline."
    | 1 Comment
  • May. 28, 2013, 8:43 AM
    Canaccord downgrades St. Jude Medical (STJ) to Sell citing "questionable earnings quality," a less-than-enthusiastic take on the company's product pipeline, the potential for CRM market share loss, and an "overextended valuation." Price target maintained at $35.
    | 1 Comment
  • May. 2, 2013, 2:56 PM
    St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 31. Ex-div date June 26. (PR)
    | Comment!
  • Apr. 17, 2013, 5:50 PM
    Volcano (VOLC) files a lawsuit against St. Jude Medical (STJ) for patent infringement, accusing STJ of violating its patent on certain guide wire methods used in its devices. The suit is just another salvo in an ongoing patent war between the two companies over pressure wire technology used their heart devices. The war actually began nearly three years ago, when STJ filed suit against VOLC for infringement of 5 of its own patents for pressure guide wire products.
    | Comment!
  • Apr. 17, 2013, 8:20 AM
    From St. Jude's (STJ) earnings call. Lowers 2013 sales guidance to $5.36-5.48B, representing a cut of $107M at the midpoint. Analysts expect $5.7B. The lower forecast is due to changes in currency assumptions and a more cautious outlook in its cardiovascular business. Expects currency neutral sales growth of -1% to +2%. (Q1 earnings)
    | Comment!
  • Apr. 17, 2013, 8:10 AM
    More on St. Jude Medical (STJ) Q1: net profit +5% to $223M, with the company enjoying a $21M tax benefit but taking $61M in charges, primarily related to restructuring and acquisition activities. Forex fluctuations hurt sales by $17M. Sales breakdown: Cardiac Rhythm Management -8% to $678M; Atrial Fibrillation +5% to $233M; total cardiovascular sales -2% to $328M. Expects Q2 EPS of $0.93-$0.95 vs consensus of 0.94 and FY EPS of $3.68-$3.73 vs $3.95. (PR)
    | Comment!
  • Apr. 17, 2013, 7:31 AM
    St. Jude Medical (STJ): Q1 EPS of $0.92 beats by $0.01. Revenue of $1.34B (-4% Y/Y) misses by $0.02B. (PR)
    | Comment!
  • Apr. 17, 2013, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT
    | Comment!
  • Apr. 16, 2013, 5:30 PM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT
    | Comment!
  • Apr. 5, 2013, 5:00 AM
    St. Jude Medical (STJ) has been hit with lawsuits in California that allege that defects with the manufacturing and oversight of its now recalled Riata heart defibrillator "leads" injured or killed over 30 patients. The suits could have a wider impact, as they seek to get round a 2008 Supreme Court ruling that protected medical-device companies from product-liability claims as long as they complied with FDA standards.
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.